---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-003854"
form_type: "8-K"
ticker: null
cik: "0001261249"
company_name: "AGILE THERAPEUTICS INC"
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:21:22.409922+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Agile Therapeutics receives final Nasdaq delisting notice; stock to trade on OTC Markets from March 26

## Summary
- Delisting due to failure to maintain minimum stockholders' equity of $2.5M per Nasdaq Listing Rule 5550(b)(1).
- Trading suspended on Nasdaq at open March 26, 2024; common stock to trade on OTC Markets under symbol AGRX.
- Company does not plan to appeal the Nasdaq Hearings Panel's determination.
- Company expects to continue operations and explore strategic opportunities to maximize Twirla growth.
- Common stock will remain registered under the Exchange Act; company will continue SEC filings.

## SEC filing metadata
- accession: 0001558370-24-003854
- form_type: 8-K
- cik: 0001261249
- company_name: AGILE THERAPEUTICS INC
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1261249/000155837024003854/0001558370-24-003854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1261249/000155837024003854/agrx-20240322x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-003854
- JSON: https://secwatch.observer/filing/0001558370-24-003854.json
- Plain text: https://secwatch.observer/filing/0001558370-24-003854.txt

## Key facts
- Listing & Compliance Notices
  AGILE THERAPEUTICS INC received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: disclosed, on March 27, 2023, the Company received a letter from the Nasdaq Listing Qualifications Department (the “Staff”) indicating that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder’s equity of at least $2,500,000 (the “Rule”). On June 2, 2023, based on the Staff’s review of the materials submitted by the Company, the Staff granted the Company’s request for an extension until September 25
  evidence_url: https://www.sec.gov/Archives/edgar/data/1261249/000155837024003854/0001558370-24-003854-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.